|Videos|December 15, 2020
Oral Semaglutide: Cardiovascular Outcomes, Safety, and Tolerability
The safety profile of oral semaglutide across the PIONEER trials was shown to be consistent with other glucagon-like peptide-1 receptor agonists (GLP-1RAs).
Click PLAY to watch the video abstract.
Click
Click
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Content
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
How Do GLP-1 Agonists Fit Into Stroke Care?
3
Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making
4
Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD
5
